AstraZeneca’s Covid-19 vaccine has shown 79 percent efficacy against symptomatic disease and 100% efficacy against severe disease and hospitalization in a new, US-based clinical trial, the company says.
This new data came from a Phase 3 clinical trial conducted in the US, Chile and Peru.
According to AstraZeneca, the findings from the new Phase 3 trial, which included more than 32,000 participants, may boost confidence in the vaccine, which was originally developed by the University of Oxford.
The Oxford-AstraZeneca vaccine was the subject of controversy earlier in the month when a number of European countries including Norway, France and Denmark decided to temporarily suspend its rollout due to reports of blood clotting in patients post inoculation.
AstraZeneca says it plans to submit the findings to a scientific journal for peer review.
Related posts:
COVID-19: Symptomatic patients in Kano narrate their ordeal
Vitamin D supplements protect against severe asthma attacks – Research
Ondo Cleric advocates severe punishment for looters
Five persons injured as severe turbulence forces Delta flight to land in Reno
Severe drought in Namibia puts over 500,000 at risk
COVID-19: The pandemic has put nat’l health systems under severe strain- Osinbajo
Severe rains, floods hit Sydney, South Wales coast in Australia
At least nine persons dead after severe storm hit eastern Australia
